Pediatric MATCH starts to accrue children with recurrent and refractory cancers

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

NCI and the Children’s Oncology Group opened enrollment in Pediatric Molecular Analysis for Therapy Choice—Pediatric MATCH—a long-awaited precision medicine trial.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Paul Goldberg
Editor & Publisher

YOU MAY BE INTERESTED IN

Paul Goldberg
Editor & Publisher

Login